Renaissance Technologies’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Renaissance Technologies’s Portfolio EFTR Stock Details EFTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,131	Closed	-$17K	–	4229
2023 Q3	$17K	Sell	1,131 -34,105	-97%	-$592K	﹤0.01%	3543
2023 Q2	$731K	Buy	35,236 +29,480	+512%	+$498K	﹤0.01%	2672
2023 Q1	$51K	Sell	5,756 -3,040	-35%	-$36.9K	﹤0.01%	3663
2022 Q4	$94K	Buy	8,796 +980	+13%	+$12.4K	﹤0.01%	3642
2022 Q3	$112K	Buy	7,816 +6,644	+567%	+$130K	﹤0.01%	3556
2022 Q2	$42K	Buy	+1,172	New	+$70.9K	﹤0.01%	4020

Other funds holding EFTR

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SIMG

Sonora Investment Management Group Tucson, Arizona $1.41B AUM 20.58% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Renaissance Technologies's EFTR Position: Q4 2023 in Review

Renaissance Technologies sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q4 2023, closing a stake of 1,131 shares — an estimated $17K sold.

Renaissance Technologies first reported a position in EFTR in Q2 2022 and held it in 6 quarters. The position peaked at $731K in Q2 2023. 25 funds tracked by Wall St. Rank hold EFTR as of Q4 2023.

Renaissance Technologies reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Renaissance Technologies sold 1,131 eFFECTOR Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $17K.
Renaissance Technologies first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q2 2022 and held it in 6 quarters.
Renaissance Technologies's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $731K in Q2 2023.
25 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Renaissance Technologies's 13F filing for Q4 2023, filed 13 Feb 2024.